Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.
Breaking News:
- Faraday Future Completes Delivery of EAI Robots in Texas, Expanding “Robot & Vehicle + Education” and “Robot & Vehicle + Performance” Scenarios
- NTT DATA unveils NVIDIA-powered enterprise AI factories to support secure AI adoption and help clients drive measurable ROI
- G-SHOCK Introduces the GA-2100K Series Inspired by the Energy of Nightlife
- Alteryx Accelerates its Next Phase of Growth with AI-Ready Data and Automation at Enterprise Scale
- Dubai Chamber of Commerce organises 35 meetings with Business Groups and Councils to support private sector resilience
- A Feast, Family & Festivities: Celebrate Eid at The Spicery from AED 99
- Faraday Future Completes Delivery of EAI Robots in Texas, Expanding “Robot & Vehicle + Education” and “Robot & Vehicle + Performance” Scenarios
- Resilience, Strategic Adaptation, and Forward Momentum
Friday, March 13
